文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA PET/CT用于前列腺癌初始分期是否具有成本效益?基于proPSMA试验的欧洲国家和美国首次结果

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-07-10

基于proPSMA试验的临床数据,从比利时、德国、意大利、荷兰和美国选定中心的报销与计费信息中获取PSMA PET/CT和常规影像的成本,采用澳大利亚成本效益研究的扫描时长和决策树进行分析。结果显示,与澳大利亚情况不同,PSMA PET/CT在欧洲和美国研究中心的成本主要增加,扫描时长对成本效益有主要影响,但准确诊断的成本相对于不准确诊断的潜在后续成本似乎合理偏低。作者认为从卫生经济学角度看使用PSMA PET/CT是合适的,但需在前瞻性初始诊断患者评估中验证。

要点

  • 基于proPSMA试验数据,PSMA PET/CT在欧洲和美国研究中心的成本主要高于常规影像。
  • 扫描时长对PSMA PET/CT的成本效益有主要影响。
  • 作者认为从卫生经济学角度使用PSMA PET/CT合适,但需前瞻性评估验证。

核心结论

  • 作者认为从卫生经济学角度使用PSMA PET/CT是合适的,但需在前瞻性初始诊断患者评估中验证。

研究设计与样本

  • 成本效益分析,临床诊断准确性数据来自proPSMA试验。
  • 成本数据来自比利时、德国、意大利、荷兰和美国选定中心的国家卫生系统报销和个体计费信息。
  • 扫描时长和决策树采用澳大利亚成本效益研究以保持可比性。

主要发现

  • 与澳大利亚情况不同,PSMA PET/CT在欧洲和美国研究中心的成本主要增加。
  • 扫描时长对成本效益有主要影响。
  • 使用PSMA PET/CT进行准确诊断的成本相对于不准确诊断的潜在后续成本似乎合理偏低。

临床怎么用

  • 作者认为从卫生经济学角度使用PSMA PET/CT是合适的,但需在前瞻性初始诊断患者评估中验证。

局限性

  • 需在前瞻性初始诊断患者评估中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The proPSMA trial at ten Australian centers demonstrated increased sensitivity and specificity for PSMA PET/CT compared to conventional imaging regarding metastatic status in primary high-risk prostate cancer patients. A cost-effectiveness analysis showed benefits of PSMA PET/CT over conventional imaging for the Australian setting. However, comparable data for other countries are lacking. Therefore, we aimed to verify the cost-effectiveness of PSMA PET/CT in several European countries as well as the USA. METHODS: Clinical data on diagnostic accuracy were derived from the proPSMA trial. Costs for PSMA PET/CT and conventional imaging were taken from reimbursements of national health systems and individual billing information of selected centers in Belgium, Germany, Italy, the Netherlands, and the USA. For comparability, scan duration and the decision tree of the analysis were adopted from the Australian cost-effectiveness study. RESULTS: In contrast to the Australian setting, PSMA PET/CT was primarily associated with increased costs in the studied centers in Europe and the USA. Mainly, the scan duration had an impact on the cost-effectiveness. However, costs for an accurate diagnosis using PSMA PET/CT seemed reasonably low compared to the potential consequential costs of an inaccurate diagnosis. CONCLUSION: We assume that the use of PSMA PET/CT is appropriate from a health economic perspective, but this will need to be verified by a prospective evaluation of patients at initial diagnosis.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Holzgreve A, Unterrainer M, Calais J, et al. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023. PMID: 37428216. doi:10.1007/s00259-023-06332-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。